Locally Advanced Rectal Cancer (LARC) Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Locally Advanced Rectal Cancer (LARC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1

NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Akamis Bio30 enrolled6 locationsNCT06459869
Recruiting

Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Beijing Friendship Hospital60 enrolled1 locationNCT07393048
Recruiting
Phase 2

SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
First Affiliated Hospital of Zhejiang University116 enrolled1 locationNCT06864013
Recruiting
Phase 2

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
First Affiliated Hospital of Wenzhou Medical University30 enrolled1 locationNCT07347951
Recruiting

Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
National Cancer Institute, Naples50 enrolled2 locationsNCT07269249
Recruiting
Phase 2

Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.

Locally Advanced Rectal Cancer (LARC)
brenner baruch134 enrolled2 locationsNCT06940388
Recruiting
Phase 2

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences228 enrolled2 locationsNCT07040098
Recruiting
Phase 3

Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study

RadiotherapyImmunotherapyLocally Advanced Rectal Cancer (LARC)+2 more
West China Hospital184 enrolled1 locationNCT07020247
Recruiting
Not Applicable

Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Centre Hospitalier Universitaire Saint Pierre20 enrolled1 locationNCT06761287
Recruiting
Not Applicable

Application of PET/MRI in the Evaluation of the Efficacy of Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer (LARC)
Peking Union Medical College Hospital30 enrolled1 locationNCT06653452